Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment.

Vascular endothelial growth factor (VEGF) B effects blood vessel formation by binding to VEGF receptor 1. To study the specifics of the biological profile of VEGF-B in both physiological and pathological angiogenesis, a neutralising anti-VEGF-B antibody (2H10) that functions by inhibiting the binding of VEGF-B to VEGF receptor 1 was developed. Here, we present the structural features of the 'highly ordered' interaction of the Fab fragment of this antibody (Fab-2H10) with VEGF-B. Two molecules of Fab-2H10 bind to symmetrical binding sites located at each pole of the VEGF-B homodimer, giving a unique U-shaped topology to the complex that has not been previously observed in the VEGF family. VEGF-B residues essential for binding to the antibody are contributed by both monomers of the cytokine. Our detailed analysis reveals that the neutralising effect of the antibody occurs by virtue of the steric hindrance of the receptor-binding interface. These findings suggest that functional complementarity between VEGF-B and 2H10 can be harnessed both in analysing the therapeutic potential of VEGF-B and as an antagonist of receptor activation.

[1]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[2]  D. Wigley,et al.  The third IgG-binding domain from streptococcal protein G. An analysis by X-ray crystallography of the structure alone and in a complex with Fab. , 1994, Journal of molecular biology.

[3]  P D Scotney,et al.  Human vascular endothelial growth factor B: Characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies , 2002, Clinical and experimental pharmacology & physiology.

[4]  Seppo Ylä-Herttuala,et al.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.

[5]  G. Cohen,et al.  Interactions of protein antigens with antibodies. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  D S Moss,et al.  Main-chain bond lengths and bond angles in protein structures. , 1993, Journal of molecular biology.

[7]  R J Read,et al.  Pushing the boundaries of molecular replacement with maximum likelihood. , 2003, Acta crystallographica. Section D, Biological crystallography.

[8]  Charles Eigenbrot,et al.  Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor , 1997, Cell.

[9]  G. Kay,et al.  Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. , 2000, Circulation research.

[10]  N. Guex,et al.  SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling , 1997, Electrophoresis.

[11]  Sachdev S Sidhu,et al.  Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. , 2006, Journal of molecular biology.

[12]  Xuri Li,et al.  Isoform-specific Expression of VEGF-B in Normal Tissues and Tumors , 2001, Growth factors.

[13]  F. Winkler,et al.  Neutralizing epitopes on the extracellular interferon gamma receptor (IFNgammaR) alpha-chain characterized by homolog scanning mutagenesis and X-ray crystal structure of the A6 fab-IFNgammaR1-108 complex. , 1997, Journal of molecular biology.

[14]  Jens Schneider-Mergener,et al.  Crystallographic Analysis of Anti-p24 (HIV-1) Monoclonal Antibody Cross-Reactivity and Polyspecificity , 1997, Cell.

[15]  M. Ultsch,et al.  Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab* , 2006, Journal of Biological Chemistry.

[16]  R L Stanfield,et al.  Antibody-antigen interactions: new structures and new conformational changes. , 1994, Current opinion in structural biology.

[17]  A. D. de Vos,et al.  Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. , 1999, Journal of molecular biology.

[18]  A. Lesk,et al.  Conformations of immunoglobulin hypervariable regions , 1989, Nature.

[19]  Robert M. Sweet,et al.  Macromolecular Crystallography: Part A , 1997 .

[20]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[21]  G. Kay,et al.  Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. , 2003, Arthritis and rheumatism.

[22]  A. D. de Vos,et al.  The Crystal Structure of Placental Growth Factor in Complex with Domain 2 of Vascular Endothelial Growth Factor Receptor-1* , 2004, Journal of Biological Chemistry.

[23]  A. Lesk,et al.  Standard conformations for the canonical structures of immunoglobulins. , 1997, Journal of molecular biology.

[24]  L. Lally.  The CCP 4 Suite — Computer programs for protein crystallography , 1998 .

[25]  J. Thornton,et al.  Satisfying hydrogen bonding potential in proteins. , 1994, Journal of molecular biology.

[26]  A. Zemla,et al.  Antibody elbow angles are influenced by their light chain class. , 2006, Journal of molecular biology.

[27]  G. N. Ramachandran,et al.  Conformation of polypeptides and proteins. , 1968, Advances in protein chemistry.

[28]  G. Kay,et al.  Transgenic Overexpression of Vascular Endothelial Growth Factor-B Isoforms by Endothelial Cells Potentiates Postnatal Vessel Growth In Vivo and In Vitro , 2005, Circulation research.

[29]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[30]  Sachdev S Sidhu,et al.  Synthetic antibodies from a four-amino-acid code: a dominant role for tyrosine in antigen recognition. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  L. Fabri,et al.  Purification and refolding of vascular endothelial growth factor‐B , 2000, Protein science : a publication of the Protein Society.

[33]  Gerald Liew,et al.  Ranibizumab for neovascular age-related macular degeneration. , 2007, The New England journal of medicine.

[34]  A Tramontano,et al.  Conformations of the third hypervariable region in the VH domain of immunoglobulins. , 1998, Journal of molecular biology.

[35]  S. Eddahibi,et al.  Role of VEGF-B in the lung during development of chronic hypoxic pulmonary hypertension. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[36]  Seth M Steinberg,et al.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. , 2003, The New England journal of medicine.

[37]  Y. Kimura,et al.  Epiadryamicin concentration in experimental hepatic metastases after bolus or continous infusion through systemic or locoregional routes. , 2003 .

[38]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. D. de Vos,et al.  VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. , 1998, Structure.

[41]  G. Hu,et al.  The crystal structure of human angiogenin in complex with an antitumor neutralizing antibody. , 2003, Structure.

[42]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[43]  A. Nash,et al.  Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding. , 2006, Journal of molecular biology.

[44]  S. Fox,et al.  VEGF‐B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis , 2001, The Journal of pathology.

[45]  B. Olffson.  Vascular endothelial grouth facter B, a novel growth facter for endothelial cells , 1996 .

[46]  P. Carmeliet,et al.  Reevaluation of the Role of VEGF-B Suggests a Restricted Role in the Revascularization of the Ischemic Myocardium , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[47]  N. Ferrara,et al.  Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.

[48]  M. Mage.  Preparation of Fab fragments from IgGs of different animal species. , 1980, Methods in enzymology.

[49]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[50]  A. Lesk,et al.  Canonical structures for the hypervariable regions of immunoglobulins. , 1987, Journal of molecular biology.